Mylan's CEO pay structure incentivizes EpiPen price hikes

Despite all of the scrutiny and anger directed at Mylan, the maker of the EpiPen allergy treatment, the company's CEO will not say firmly that the price of the drug will be lowered after increasing by about 500% in less than a decade.

When asked about the matter, Mylan CEO Heather Bresch told CNBC only that she would be looking forward to working with Washington to find solutions for problems in the US healthcare system.

Not really an answer, you may notice.

In fact, it's reasonable to assume that — until this week, at least — Mylan would have kept increasing the price of EpiPen through 2018.

Why? Well it all ties into Mylan's executive compensation plan. If the company can get to earnings per share of $5.40 (the goal is actually $6, but there's some wiggle room) by 2018, Bresch and her team stand to make millions in stock...

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.